Improved resistance to serum oxidation in Gilbert's syndrome: A mechanism for cardiovascular protection
Received 27 September 2007; received in revised form 1 November 2007; accepted 15 November 2007. published online 03 January 2008.
Abstract
Bilirubin is a potent antioxidant, however, uncertainty surrounds its physiological importance. Individuals with Gilbert's syndrome (GS) have increased circulating bilirubin and a reduced prevalence of cardiovascular disease (CVD). The aim of this study was to investigate mechanisms that may link bilirubin to protection from CVD seen in GS by examining markers of antioxidant and oxidative stress status and the susceptibility of serum to oxidation. Nine individuals with GS and twelve controls, matched for age, height and weight, were assessed for plasma antioxidant status, red blood cell antioxidant enzyme activities, plasma malondialdehyde, the susceptibility of serum to copper (Cu2+) induced oxidation and blood lipid profile. Individuals with GS had significantly elevated unconjugated bilirubin (GS: 26.0±6.4; control: 9.7±3.0μmol/L; P<0.001), increased trolox equivalent antioxidant capacity (GS: 1.59±0.07; control: 1.52±0.07mmol/L trolox Equ; P=0.035) and ferric reducing ability of plasma (GS: 1.09±0.16; control: 0.92±0.14mmol/L Fe2+ Equ; P=0.024). The lag phase of serum oxidation was significantly longer in the GS group (GS: 121.4±10.5; control: 106.8±14.6min; P=0.020) and was positively correlated with the bilirubin concentration (r=0.451, P=0.040). A trend toward elevated HDL:LDL ratio was observed in GS (GS 0.96±0.31; control: 0.73±0.21; P=0.072). In summary, individuals with GS have an increased circulating antioxidant status and an improved resistance to serum oxidation which may partially explain their reduced prevalence of CVD.
aSchool of Human Movement Studies, University of Queensland, St. Lucia, Queensland 4067, Australia
bSchool of Molecular and Microbial Sciences, University of Queensland, St. Lucia, Queensland 4067, Australia
cSchool of Pharmacy, University of Queensland, St. Lucia, Queensland 4067, Australia
dLaunceston General Hospital, Launceston, Tasmania 7250, Australia
eBiopharma Pty. Ltd., 2/67 Richland Avenue, Coopers Plains, Queensland 4108, Australia
Corresponding author at: School of Human Movement Studies, Blair Drive, University of Queensland, St. Lucia, Queensland 4067, Australia. Tel.: +61 7 3365 6767; fax: +61 7 3365 6877.